Clinical studies have shown that dCK gene polymorphism (such as rs11158728 SNP) can reduce the enzyme (Dash et al., 2024), and the objective response rate (ORR) of pancreatic cancer patients with low activity genotype decreases (Hatori et al., 2024). The gene discussed is DCK; the disease is pancreatic neoplasm.